Manufacturer of Controlled Substances; Notice of Registration, 64676-64677 [E7-22468]
Download as PDF
<![CDATA[
64676
Federal Register / Vol. 72, No. 221 / Friday, November 16, 2007 / Notices
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: November 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22464 Filed 11–15–07; 8:45 am]
Dated: October 31, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22521 Filed 11–15–07; 8:45 am]
Manufacturer of Controlled
Substances; Notice of Registration
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on PROD1PC66 with NOTICES
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated June 26, 2007, and
published in the Federal Register on
July 3, 2007, (72 FR 36481), Cambrex
Charles City, Inc., 1205 11th Street,
Charles City, Iowa 50616, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Codeine (9050), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture
the listed controlled substance for sale
as an intermediate to other opiates and
supply as API to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambrex Charles City, Inc. to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
investigated Cambrex Charles City, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
VerDate Aug<31>2005
21:48 Nov 15, 2007
Jkt 214001
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
By Notice dated June 7, 2007, and
published in the Federal Register on
June 20, 2007, (72 FR 34039–34040),
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Hydromorphone (9150), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture
the listed controlled substance for sale
to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambrex Charles City, Inc. to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
investigated Cambrex Charles City, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: November 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22513 Filed 11–15–07; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
Frm 00103
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated June 26, 2007, and
published in the Federal Register on
July 5, 2007, (72 FR 36729), Cambrex
Charles City, Inc., 1205 11th Street,
Charles City, Iowa 50616, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Morphine (9300), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture
the listed controlled substance for sale
as an intermediate to generic drug
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambrex Charles City, Inc. to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
investigated Cambrex Charles City, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: November 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22517 Filed 11–15–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated July 31, 2007, and
published in the Federal Register on
August 9, 2007, (72 FR 44860), Cambrex
North Brunswick, Inc., Technology
Centre of New Jersey, 661 Highway One,
North Brunswick, New Jersey 08902,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
E:\FR\FM\16NON1.SGM
16NON1
64677
Federal Register / Vol. 72, No. 221 / Friday, November 16, 2007 / Notices
manufacturer of the basic classes of
controlled substances listed in schedule
I and II:
Drug
Schedule
N-Ethylamphetamine (1475) ........................................................................................................................................................................
Tetrahydrocannabinols (7370) .....................................................................................................................................................................
2,5-Dimethoxyamphetamine (7396) ............................................................................................................................................................
3,4-Methylenedioxyamphetamine (7400) ....................................................................................................................................................
4-Methoxyamphetamine (7411) ...................................................................................................................................................................
Amphetamine (1100) ...................................................................................................................................................................................
Methamphetamine (1105) ...........................................................................................................................................................................
Methylphenidate (1724) ...............................................................................................................................................................................
Pentobarbital (2270) ....................................................................................................................................................................................
Phenylacetone (8501) .................................................................................................................................................................................
Hydromorphone (9150) ...............................................................................................................................................................................
Hydrocodone (9193) ....................................................................................................................................................................................
Methadone (9250) .......................................................................................................................................................................................
Methadone intermediate (9254) ..................................................................................................................................................................
Morphine (9300) ..........................................................................................................................................................................................
Sufentanil (9740) .........................................................................................................................................................................................
Fentanyl (9801) ...........................................................................................................................................................................................
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambrex North Brunswick, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cambrex North Brunswick,
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22468 Filed 11–15–07; 8:45 am]
BILLING CODE 4410–09–P
Dated: November 6, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22505 Filed 11–15–07; 8:45 am]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on PROD1PC66 with NOTICES
Road, Andover, Massachusetts 01810,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Morphine (9300), a
basic class of controlled substance listed
in schedule II.
The company plans to utilize small
quantities of the listed controlled
substance in the preparation of
analytical standards.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 15, 2008.
Manufacturer of Controlled
Substances; Notice of Application
BILLING CODE 4410–09–P
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on June 6, 2007,
Cambridge Isotope Lab, 50 Frontage
VerDate Aug<31>2005
21:48 Nov 15, 2007
Jkt 214001
PO 00000
Frm 00104
Fmt 4703
Sfmt 4703
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on October 16, 2007,
Cody Laboratories, 601 Yellowstone
Avenue, Cody, Wyoming 82414, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule II:
Drug
Codeine (9050) .............................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Schedule
II
II
II
II
The company plans on manufacturing
the listed controlled substances in bulk
for sale to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, VA 22152; and must be
filed no later than January 15, 2008.
E:\FR\FM\16NON1.SGM
16NON1
]]>Agencies
[Federal Register Volume 72, Number 221 (Friday, November 16, 2007)]
[Notices]
[Pages 64676-64677]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-22468]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated July 31, 2007, and published in the Federal
Register on August 9, 2007, (72 FR 44860), Cambrex North Brunswick,
Inc., Technology Centre of New Jersey, 661 Highway One, North
Brunswick, New Jersey 08902, made application by renewal to the Drug
Enforcement Administration (DEA) to be registered as a bulk
[[Page 64677]]
manufacturer of the basic classes of controlled substances listed in
schedule I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
N-Ethylamphetamine (1475)................... I
Tetrahydrocannabinols (7370)................ I
2,5-Dimethoxyamphetamine (7396)............. I
3,4-Methylenedioxyamphetamine (7400)........ I
4-Methoxyamphetamine (7411)................. I
Amphetamine (1100).......................... II
Methamphetamine (1105)...................... II
Methylphenidate (1724)...................... II
Pentobarbital (2270)........................ II
Phenylacetone (8501)........................ II
Hydromorphone (9150)........................ II
Hydrocodone (9193).......................... II
Methadone (9250)............................ II
Methadone intermediate (9254)............... II
Morphine (9300)............................. II
Sufentanil (9740)........................... II
Fentanyl (9801)............................. II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Cambrex North Brunswick, Inc. to manufacture the listed basic classes
of controlled substances is consistent with the public interest at this
time. DEA has investigated Cambrex North Brunswick, Inc. to ensure that
the company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with
21 CFR 1301.33, the above named company is granted registration as a
bulk manufacturer of the basic classes of controlled substances listed.
Dated: November 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-22468 Filed 11-15-07; 8:45 am]
BILLING CODE 4410-09-P
